Skip to main content
SpringerLink
Log in

Hormone replacement therapy (HRT) with drospirenone offers the additional benefit of blood pressure reduction in postmenopausal women

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Mallareddy M, Hanes V, White WB. Drospirenone, a new progestogen, for postmenonpausal women with hypertension. Drugs Aging 2007; 24(6): 453–66

    Article  PubMed  CAS  Google Scholar 

  2. Motivala A, Pitt B. Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens? Drugs 2007; 67(5): 647–55

    Article  PubMed  CAS  Google Scholar 

  3. Anderson GL, Limacher M, Assaf AR, et al. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004; 291(14): 1701–12

    Article  PubMed  CAS  Google Scholar 

  4. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321–33

    Article  PubMed  CAS  Google Scholar 

  5. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006; 166(9): 1027–32

    Article  PubMed  CAS  Google Scholar 

  6. Stefanick ML, Anderson GL, Margolis KL, et al. WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295(14): 1647–57

    Article  PubMed  CAS  Google Scholar 

  7. Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids 2003; 68(10–13): 891–905

    Article  PubMed  CAS  Google Scholar 

  8. Muhn P, Fuhrmann U, Fritzemeier KH, et al. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann N Y Acad Sci 1995; 761: 311–35

    Article  PubMed  CAS  Google Scholar 

  9. Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004; 7(2): 189–96

    Article  PubMed  CAS  Google Scholar 

  10. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, doubleblind, multicenter trial. Menopause 2005; 12(6): 716–27

    Article  PubMed  Google Scholar 

  11. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004; 61(4): 633–70

    Article  Google Scholar 

  12. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73(4): 837–42

    Article  PubMed  CAS  Google Scholar 

  13. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80(6): 1816–21

    Article  PubMed  CAS  Google Scholar 

  14. White WB, Pitt B, Preston RA, et al. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005; 112(13): 1979–84

    Article  PubMed  CAS  Google Scholar 

  15. White WB, Hanes V, Chauhan V, et al. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006; 48(2): 246–53

    Article  PubMed  CAS  Google Scholar 

  16. Preston RA, Alonso A, Panzitta D, et al. Additive effect of drospirenone/ 17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 2002; 15(9): 816–22

    Article  PubMed  CAS  Google Scholar 

  17. Preston RA, White WB, Pitt B, et al. Effects of drospirenone/ 17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18(6): 797–804

    Article  PubMed  CAS  Google Scholar 

  18. Preston RA, Norris PM, Alonso AB, et al. Randomized, placebocontrolled trial of the effects of drospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 2007; 14(1): 1–7

    Article  Google Scholar 

  19. Schurmann R, Blode H, Benda N, et al. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J Clin Pharmacol 2006; 46(8): 867–75

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hormone replacement therapy (HRT) with drospirenone offers the additional benefit of blood pressure reduction in postmenopausal women. Drugs Ther. Perspect 24, 12–14 (2008). https://doi.org/10.2165/00042310-200824020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200824020-00004

Keywords

Search

Navigation